Unprecedented Interest in Flow Cytometry Expands Horizons of Clinical Capabilities, says Market.us

Flow Cytometry is a laser-based and biophysical analysis technique that analyzes micelles or cells suspended within fluids. This method helps to subclassify cells and detect disease residuals. It also allows for the development of the most effective treatment plan.

Fluorescent probes such as bisoxonol can bind to proteins on cell membranes, which allows for the detection of different levels of cell damage and necrosis. This technique can also be used to understand the structure and composition of cells for cancer diagnosis, chromosome analysis, and protein expression. It is also useful in diagnosing diseases and hematological malignancies.

According to the latest report by Market.us, ” The global flow cytometry market will be worth USD 6.5 billion by 2020. The market is expected to continue growing at an 8.1% annual compound growth rate from 2021-2027.”

Flow Cytometry is an important tool in drug discovery and development. This tool is used to determine the potential targets and screen them for preclinical research. Flow Cytometry can quickly analyze large quantities of particles and provides reliable, statistically valid information on cell populations.

These capabilities combined with multiparametric approaches make flow cytometry an attractive option for drug discovery and development in the pharmaceutical and biopharmaceutical sectors.

Research on biomarkers is an important part of drug discovery and development. It is a valuable tool that can aid in clinical decisions as well as evaluate pharmacodynamics. It can increase the drug’s worth. Flow Cytometry is used in biomarker studies to monitor and differentiate cells and evaluate target expression and engagement, as well as evaluate cell functions.

Anurag Sharma, a senior research analyst at Market.us, said,” To combat the disease burden, many clinical trials are being conducted around the world. The number of clinical trials is increasing with both public and private funding. This market is partially driven by the increasing number of clinical trials and increased use of flow cytometry for various research purposes.”

Multiple research studies require multiple flow cytometry devices. Most end users need several units, including clinical labs and research facilities. This results in a significant increase in capital cost for maintenance and procurement. These instruments aren’t affordable for academic and research labs due to their limited budgets.

Indirect expenses such as maintenance and repairs can also cause higher total costs for these instruments. The high costs of product installation and associated expenses in emerging countries can prevent instrument adoption for research and clinical purposes. Because they offer advanced functionalities and features, flow cytometry tools can be expensive.

Stem cell therapy will have a significant market share. Flow Cytometry can be used to quickly identify and characterize stem cells for research and other activities. Stem cell-based therapies are being considered to treat COVID-19. Many universities and businesses are currently conducting stem cell research.

For example, in August 2020, the University of Minnesota used mesenchymal-derived stem cells (MSC), to treat COVID-19 patients and subsequent pulmonary failure. This will result in a higher demand for flow cytometers because of the growing research in this field.

This market segment holds a large share of the overall market due to the widespread adoption of early diagnosis and treatment. The market’s key players will benefit from stem cell research’s increasing market penetration, the adoption of recombinant DNA technology for antibody production, as well as the development of tandem flow cytometry technologies.

The National Clinical Trial Registry (NCT) reports that approximately 320 clinical trials for stem cell therapy were registered in Germany. Due to stem cell therapy research, flow cytometry will be more in demand.